Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lenabasum in dermatomyositis (Japan)
jRCT2080224821Phase 3Completed
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lenabasum in dermatomyositis (DM) (3 arms), sponsored by Corbus Pharmaceuticals Holdings, Inc. Started Aug 2019; status: completed.
02
Drugs
lenabasum
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on jRCT2080224821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224821.